ONCOTHERAPY SCIENCE INC. Logo
JP3202150003
726692
4564.T

ONCOTHERAPY SCIENCE INC.

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, ONCOTHERAPY SCIENCE INC. had revenue of €924.02k and net profit of -€1.6m

(EUR) September 2026
YoY
Revenue 924.02k 30.35%
Gross profit -97.11k 151.75%
Net profit -1.6m 15.56%
EBITDA -1.59m 14.98%

Fundamentals

Metric Value
Market capitalization
€32.85m
Number of shares
408.24m
52-week high/low
€0.20 - €0.0805
Dividends No
Beta
0.33
P/E ratio
-6.09
PEG ratio
-0.27
P/B ratio
2.77
P/S ratio
8.02

Company profile

OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.

Name
ONCOTHERAPY SCIENCE INC.
CEO
Junichi Shimada
Headquarters Kawasaki, kn
Japan
Website
IPO
29/09/2005
Employees 46

Ticker symbols

Exchange Symbol
Japan Exchange Group
4564.T
Frankfurt
30O.F
München
30O.MU
Düsseldorf
30O.DU
🍪

Parqet  uses cookies. Learn more